Merck Serono S.A. - Strategic SWOT Analysis Review

Date: May 4, 2015
Pages: 35
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M59F2B4BA0FEN
Leaflet:

Download PDF Leaflet

Merck Serono S.A. - Strategic SWOT Analysis Review
Merck Serono S.A. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - GlobalData’s summarization of the company’s business strategy.
  • SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
Highlights

Merck Serono S.A., (Merck Serono) is the biopharmaceutical division of Merck KGaA. It discovers, develops, manufactures and commercializes prescription medicines of both chemical and biological origin in specialist indications with focus on the neurology, cancer, immuno-oncology and immunology. Merck Serono has a broad product portfolio, which is distributed across the world through a network of distributors. The division manages four research and development centers in the US, Germany, China and Japan. It has a global presence with operations in more than 150 countries and production facilities in four countries. Merck Serono markets its products to wholesale distributors or directly to hospitals, medical centers, and pharmacies. Merck Serono is headquartered in Geneva, Switzerland.

The division seeks to strengthen its position in various countries across the world. This intent is evident from its global licensing agreement with the Spanish National Cancer Research Centre (CNIO) for the development and commercialization of new drug candidates in the field of cancer.

Merck Serono S.A. Key Recent Developments

Apr 16, 2015: Alise Reicin Joins Merck Serono as Head of Global Clinical Development
Mar 03, 2015: First contract for a clinical version of our Virtual Tumour model with Global Pharmaceutical Company, Merck
Nov 15, 2013: Merck Strengthens its Presence in China with New Pharmaceutical Manufacturing Facility
Nov 04, 2013: Merck Serono Grant for Growth Innovation Countdown for Accepting Proposals
Oct 10, 2013: Merck Serono Opens New Global Headquarters in Darmstadt

Reasons to Buy
  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
Table of Contents
List of Tables
List of Figures

SECTION 1 - ABOUT THE COMPANY

Merck Serono S.A. - Key Facts
Merck Serono S.A. - Key Employees
Merck Serono S.A. - Major Products and Services
Merck Serono S.A. - History
Merck Serono S.A. - Company Statement
Merck Serono S.A. - Locations And Subsidiaries
Head Office

SECTION 2 – COMPANY ANALYSIS

Merck Serono S.A. - Business Description
Merck Serono S.A. - SWOT Analysis
SWOT Analysis - Overview
Merck Serono S.A. - Strengths
Strength - Focused Research and Development Activities
Strength - Synergy through Merck
Strength - Widespread Geographical Presence
Merck Serono S.A. - Weaknesses
Weakness - Discontinuation/Termination
Weakness - Controversy in Serono's U.S operations
Merck Serono S.A. - Opportunities
Opportunity - Robust Product Pipeline
Opportunity - Biotech Focus
Opportunity - Market Potential – Oncology
Opportunity - Strategic Alliances and Agreements
Merck Serono S.A. - Threats
Threat - Cost Containment Pressures
Threat - Growing Parallel Trade
Threat - Uncertain R&D outcomes
Merck Serono S.A. - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Merck Serono S.A., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015
Merck Serono S.A., Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015
Merck Serono S.A., Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Apr 16, 2015: Alise Reicin Joins Merck Serono as Head of Global Clinical Development
Mar 03, 2015: First contract for a clinical version of our Virtual Tumour model with Global Pharmaceutical Company, Merck
Sep 19, 2014: Merck Serono Awards Grant for Growth Innovation (GGI) for the First Time
Aug 04, 2014: Kadimastem to Collaborate with Merck Serono to Advance Combined Efforts in Neurodegenerative Disease Area
Apr 17, 2014: Merck Serono's President & CEO Belén Garijo has Been Appointed to Board of Directors of L'Oréal
Mar 31, 2014: New Global Initiative Aims to Improve Patient Outcomes in Metastatic Colorectal Cancer
Jan 09, 2014: Merck Serono Appoints Steven Hildemann as Global Chief Medical Officer

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Merck Serono S.A., Key Facts
Merck Serono S.A., Key Employees
Merck Serono S.A., Major Products and Services
Merck Serono S.A., History
Merck Serono S.A., Key Competitors
Merck Serono S.A., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015
Merck Serono S.A., Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015
Merck Serono S.A., Recent Deals Summary

LIST OF FIGURES

Merck Serono S.A., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015
Merck Serono S.A., Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015
Skip to top


Ask Your Question

Merck Serono S.A. - Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: